Accelerate the development of
genetic therapies aimed at curing sickle cell disease.
The Cure Sickle Cell Initiative was created by the
National Heart, Lung, and Blood Institute to:
- Use emerging safe and promising genetic therapies to improve the lives of individuals with sickle cell disease.
- Actively engage the sickle cell disease community of patients, family members, caregivers and advocates to work together on a path to the cure.
- Encourage collaboration among researchers, industry, non-profit organizations, and policy-making agencies who will play a role in curing the disease.
Department of Health and Human Services (DHHS)
DHHS Health Resources and Services Administration (HRSA)
DHHS Office of Minority Health (OMH)
Centers for Disease Control and Prevention (CDC)
Centers for Medicare & Medicaid Services (CMS)
Food and Drug Administration (FDA)
National Institutes of Health (NIH)
National Institute of Standards and Technology (NIST)
Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
Center for International Blood & Marrow Transplant Research (CIBMTR)
Production Assistance for Cellular Therapies (PACT)
Sickle Cell Disease Implementation Consortium (SCDIC)
Biologic Specimen and Data Repository (BioLINCC)
Gene Therapy Resource Program
Beckman Research Institute/City of Hope
Boston Children’s Hospital
Case Western University
Fred Hutchinson Cancer Research Center
Medical College of Wisconsin
Research Triangle Institute (RTI)
University of California San Francisco
University of California Los Angeles
University of Washington
MEMORANDUM OF UNDERSTANDING (MOU)
American Society of Hematology (ASH)
California Institute for Regenerative Medicine (CIRM)